This week I saw a patient about to start chemotherapy for breast cancer.  She was deciding whether to take a drug that would reduce her recurrence risk by 50%, or the more aggressive regimen recommended by her oncologist, which would reduce her risk by another 6% but carries the risk of additional longlasting side effects.1… Read More »